Supernus Pharmaceuticals - SUPN Stock Forecast, Price & News

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Supernus Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" SUPN shares.
View SUPN analyst ratings or view top-rated stocks.

1 Wall Street research analysts have issued 12-month price objectives for Supernus Pharmaceuticals' stock. Their SUPN share price forecasts range from $47.00 to $47.00. On average, they expect the company's stock price to reach $47.00 in the next year. This suggests a possible upside of 15.5% from the stock's current price.
View analysts price targets for SUPN or view top-rated stocks among Wall Street analysts.

Supernus Pharmaceuticals' stock was trading at $35.67 at the start of the year. Since then, SUPN shares have increased by 14.0% and is now trading at $40.68.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 12th 2023.
View our SUPN earnings forecast.

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) issued its quarterly earnings results on Tuesday, November, 8th. The specialty pharmaceutical company reported $0.03 earnings per share for the quarter, missing the consensus estimate of $0.32 by $0.29. The specialty pharmaceutical company had revenue of $177.35 million for the quarter, compared to analysts' expectations of $173.22 million. Supernus Pharmaceuticals had a trailing twelve-month return on equity of 4.51% and a net margin of 5.72%.

Supernus Pharmaceuticals issued an update on its FY 2022 earnings guidance on Thursday, December, 8th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $650.00 million-$680.00 million, compared to the consensus revenue estimate of $674.36 million.

20 employees have rated Supernus Pharmaceuticals Chief Executive Officer Jack A. Khattar on Glassdoor.com. Jack A. Khattar has an approval rating of 81% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Supernus Pharmaceuticals investors own include NVIDIA (NVDA), AbbVie (ABBV), Gilead Sciences (GILD), Alibaba Group (BABA), Exelixis (EXEL), Pfizer (PFE), GW Pharmaceuticals (GWPH), Netflix (NFLX), Corcept Therapeutics (CORT) and Cara Therapeutics (CARA).

Supernus Pharmaceuticals trades on the NASDAQ under the ticker symbol "SUPN."

Supernus Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Stephens Investment Management Group LLC (2.97%), Rice Hall James & Associates LLC (1.15%), Congress Asset Management Co. MA (0.94%), Tributary Capital Management LLC (0.63%), Scout Investments Inc. (0.57%) and Phocas Financial Corp. (0.32%). Insiders that own company stock include Frederick M Hudson, Gregory S Patrick, Jack A Khattar, Padmanabh P Bhatt, Stefan KF Schwabe and Tami Tillotson Martin.
View institutional ownership trends.

Shares of SUPN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SUPN stock can currently be purchased for approximately $40.68.

Supernus Pharmaceuticals (NASDAQ:SUPN) has a market capitalization of $2.20 billion and generates $579.78 million in revenue each year. The specialty pharmaceutical company earns $53.42 million in net income (profit) each year or $0.64 on an earnings per share basis.

The company employs 575 workers across the globe.

Supernus Pharmaceuticals' mailing address is 1550 E GUDE DR, ROCKVILLE MD, 20850. The official website for the company is www.supernus.com. The specialty pharmaceutical company can be reached via phone at (301) 838-2500, via email at gpatrick@supernus.com, or via fax at 301-838-2501.